Apollon Wealth Management LLC Has $250,000 Holdings in The Clorox Company (NYSE:CLX)

Apollon Wealth Management LLC decreased its position in The Clorox Company (NYSE:CLX) by 4.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,532 shares of the company’s stock after selling 77 shares during the period. Apollon Wealth Management LLC’s holdings in Clorox were worth $250,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Insight Folios Inc boosted its position in shares of Clorox by 3.0% during the 3rd quarter. Insight Folios Inc now owns 2,195 shares of the company’s stock valued at $358,000 after purchasing an additional 63 shares in the last quarter. Fiduciary Group LLC boosted its holdings in shares of Clorox by 0.4% during the 2nd quarter. Fiduciary Group LLC now owns 19,050 shares of the company’s stock worth $2,600,000 after buying an additional 72 shares in the last quarter. GHP Investment Advisors Inc. grew its position in shares of Clorox by 2.0% during the 2nd quarter. GHP Investment Advisors Inc. now owns 3,634 shares of the company’s stock worth $496,000 after buying an additional 72 shares during the period. SPC Financial Inc. lifted its position in shares of Clorox by 2.2% during the 2nd quarter. SPC Financial Inc. now owns 3,485 shares of the company’s stock valued at $476,000 after acquiring an additional 75 shares during the period. Finally, Massmutual Trust Co. FSB ADV boosted its stake in Clorox by 17.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 510 shares of the company’s stock worth $83,000 after acquiring an additional 75 shares in the last quarter. Institutional investors own 78.53% of the company’s stock.

Insider Activity

In related news, EVP Angela C. Hilt sold 1,733 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $165.52, for a total value of $286,846.16. Following the transaction, the executive vice president now owns 13,471 shares in the company, valued at approximately $2,229,719.92. This represents a 11.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.57% of the company’s stock.

Clorox Price Performance

Shares of NYSE CLX opened at $169.14 on Tuesday. The company has a quick ratio of 0.62, a current ratio of 1.00 and a debt-to-equity ratio of 11.08. The company has a market capitalization of $20.94 billion, a PE ratio of 58.93, a PEG ratio of 3.10 and a beta of 0.41. The stock’s 50 day moving average price is $162.53 and its 200-day moving average price is $147.73. The Clorox Company has a twelve month low of $127.60 and a twelve month high of $169.21.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.50. The firm had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.64 billion. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The business’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 EPS. On average, equities analysts anticipate that The Clorox Company will post 6.85 EPS for the current year.

Clorox Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, November 7th. Shareholders of record on Wednesday, October 23rd were paid a $1.22 dividend. This represents a $4.88 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date of this dividend was Wednesday, October 23rd. Clorox’s payout ratio is 170.03%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. DA Davidson lifted their price target on shares of Clorox from $153.00 to $171.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. TD Cowen raised Clorox from a “sell” rating to a “hold” rating and upped their price target for the stock from $155.00 to $170.00 in a research note on Wednesday, November 6th. Barclays raised their price objective on Clorox from $137.00 to $139.00 and gave the company an “underweight” rating in a research note on Friday, November 1st. Citigroup upped their target price on Clorox from $165.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, September 6th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Clorox from $148.00 to $174.00 and gave the company a “neutral” rating in a research report on Friday, October 11th. Five equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Clorox has an average rating of “Hold” and an average price target of $155.00.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.